Histone acetylation modifications: A potential targets for the diagnosis and treatment of papillary thyroid cancer.
Thyroid cancer is a common malignancy of the endocrine system, with papillary thyroid cancer (PTC) being the most common type of pathology.
APA
Chen C, Liu J (2022). Histone acetylation modifications: A potential targets for the diagnosis and treatment of papillary thyroid cancer.. Frontiers in oncology, 12, 1053618. https://doi.org/10.3389/fonc.2022.1053618
MLA
Chen C, et al.. "Histone acetylation modifications: A potential targets for the diagnosis and treatment of papillary thyroid cancer.." Frontiers in oncology, vol. 12, 2022, pp. 1053618.
PMID
36523971
Abstract
Thyroid cancer is a common malignancy of the endocrine system, with papillary thyroid cancer (PTC) being the most common type of pathology. The incidence of PTC is increasing every year. Histone acetylation modification is an important part of epigenetics, regulating histone acetylation levels through histone acetylases and histone deacetylases, which alters the proliferation and differentiation of PTC cells and affects the treatment and prognosis of PTC patients. Histone deacetylase inhibitors induce histone acetylation, resulting in the relaxation of chromatin structure and activation of gene transcription, thereby promoting differentiation, apoptosis, and growth arrest of PTC cells.
같은 제1저자의 인용 많은 논문 (5)
- Surgical Resection and Reconstruction of Ameloblastoma: A 13-Year Retrospective Review.
- Next-generation sequencing for lymphoid neoplasms: Real-world utility from a clinical assay.
- Wedelolide A induces ferroptosis and apoptosis in gastric cancer via keap1/Nrf2 modulation and ROS generation.
- The pH perspective of cancer: From warburg's misconception to therapeutic targeting of pH regulating proteins.
- Optimizing adjuvant therapy under the guidance of MPR: A multicenter retrospective analysis of neoadjuvant therapy in non-small cell lung cancer.